Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | TACR1 | P25103 | 3/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.31 |
| ▸ | HRH1 | P35367 | 1/20 | 0.31 |
| ▸ | KAT2B | Q92831 | 5/20 | 0.31 |
| ▸ | TOP2A | P11388 | 1/20 | 0.31 |
| ▸ | TOP2B | Q02880 | 1/20 | 0.31 |
| ▸ | MMP1 | P03956 | 1/20 | 0.31 |
| ▸ | MMP2 | P08253 | 1/20 | 0.31 |
| ▸ | MMP9 | P14780 | 1/20 | 0.31 |
| ▸ | MMP13 | P45452 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14573710 | 1.00 | MAPK1 (0.32) | MAPK1CYP3A4CYP2C19CYP1A2CYP2C9 | |
| SCHEMBL4693900 | 1.00 | MAPK1 (0.32) | MAPK1CYP3A4CYP2C19CYP1A2CYP2C9 | |
| SCHEMBL4693897 | 1.00 | MAPK1 (0.32) | MAPK1CYP3A4CYP2C19CYP1A2CYP2C9 | |
| SCHEMBL4695318 | 0.86 | TSHR (0.37) | CYP3A4CYP2C19CYP1A2CYP2C9TACR1 | |
| SCHEMBL14573729 | 0.86 | TSHR (0.37) | CYP3A4CYP2C19CYP1A2CYP2C9TACR1 | |
| SCHEMBL14573799 | 0.84 | CYP2C19 (0.37) | MAPK1CYP3A4CYP2C19CYP1A2CYP2C9 | |
| SCHEMBL4690017 | 0.83 | COMT (0.38) | MAPK1CYP3A4CYP2C19CYP1A2CYP2C9 | |
| SCHEMBL4693921 | 0.83 | COMT (0.38) | MAPK1CYP3A4CYP2C19CYP1A2CYP2C9 | |
| SCHEMBL4690020 | 0.83 | COMT (0.38) | MAPK1CYP3A4CYP2C19CYP1A2CYP2C9 | |
| SCHEMBL14573798 | 0.83 | TACR1 (0.31) | TACR1KDM4EALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1888581-A2 | HIV-INTEGRASE INHIBITOR COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2008-02-20 | — | — | EP | disclosed |
| US-20070072831-A1 | Integrase inhibitor compounds | GILEAD SCIENCES, INC. | 2007-03-29 | — | — | US | disclosed |
| WO-2006125048-A2 | HIV-INTEGRASE INHIBITOR COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2006-11-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070072831-A1 | Integrase inhibitor compounds | TYMP, CDKN1A, PAICS | MAPK1 3304/4885CYP3A4 476/4885CYP2C19 1140/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.